Skip to main content

Advertisement

Table 1 Disease extent, measured metastatic sites and changes in mean SUVmax, PSA and ALP at 6 and 12 weeks after first administration of 223Ra

From: 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)

Subject
(disease extent)
0 weeks     6 weeks    12 weeks   
  Measured sites Mean SUVmax (range) Baseline PSA (ng/ml) Baseline ALP (U/L) SUV (range)
[% of baseline]
PSA
[% of baseline]
ALP
[% of baseline]
SUV (range)
[% of baseline]
PSA
[% of baseline]
ALP
[% of baseline]
A (6-20 metastases) C6, T6, L Sacrum, R ilium, L femur 46.4
(33.1-75.3)
370 118 31.3
(26.5-40.5) [67.5%]
210
[56.8%]
47
[39.8%]
22.1
(16.7-28.2) [47.6%]
207
[55.9%]
53
[44.9%]
B (superscan) C3, L1, L5, L femur, R tibia 15.0
(13.2-17.2)
508 761 16.0
(11.9-21.1) [106.7%]
459
[90.4%]
332
[43.6%]
3.7
(2.9-4.8) [24.7%]
350
[68.9%]
225
[29.6%]
C (6-20 metastases) L1, L3, L5, sternum, R ischium 74.6
(54.7-98)
78 129 66.7
(51.3-76.7) [89.4%]
92
[117.9%]
85
[65.9%]
38.2
(26.5-46.9) [51.2%]
57
[73.1%]
70
[54.3%]
D (>20 metastases) Skull, L scapula, T11, L3, L ilium 27.5
(20.3-35.4)
551 89 25.3
(20.6-29.5) [92%]
674 [122.3%] 53
[59.6%]
30.7
(21.1-59.4) [111.6%]
607 [110.2%] 50
[56.2%]
E (superscan) Skull, T12, L3, R ilium, R femur 22.3
(11.4-28.6)
254 393 20.3
(11-25)
[91%]
273 [107.5%] 406
[103.3%]
18.8
(9.8-24.8) [84.3%]
298 [117.3%] 290
[73.8%]